4//SEC Filing
Reynolds Cameron John 4
Accession 0001078782-20-000560
CIK 0000093314other
Filed
Jul 22, 8:00 PM ET
Accepted
Jul 23, 4:41 PM ET
Size
15.4 KB
Accession
0001078782-20-000560
Insider Transaction Report
Form 4
VOLITIONRX LTDVNRX
Reynolds Cameron John
DirectorPRESIDENT AND CEO
Transactions
- Tax Payment
Common Stock
2020-07-21$3.95/sh−43,627$172,327→ 1,142,373 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-07-21−50,000→ 0 totalExercise: $3.00From: 2016-02-18Exp: 2020-08-18→ Common Stock (50,000 underlying) - Exercise/Conversion
Common Stock
2020-07-21$2.50/sh+50,000$125,000→ 1,176,273 total - Tax Payment
Common Stock
2020-07-21$3.95/sh−40,273$159,078→ 1,136,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-07-21−50,000→ 0 totalExercise: $2.50From: 2015-02-18Exp: 2020-08-18→ Common Stock (50,000 underlying) - Exercise/Conversion
Common Stock
2020-07-21$3.00/sh+50,000$150,000→ 1,186,000 total
Holdings
- 34,076(indirect: By Spouse)
Common Stock
- 1,007,718(indirect: Concord International, Inc.)
Common Stock
Footnotes (2)
- [F1]Represents the aggregate number of shares of Common Stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise and to satisfy the tax withholding obligations of the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction.
- [F2]The shares of Common Stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of Common Stock held by Concord International, Inc.
Documents
Issuer
VOLITIONRX LTD
CIK 0000093314
Entity typeother
Related Parties
1- filerCIK 0001340610
Filing Metadata
- Form type
- 4
- Filed
- Jul 22, 8:00 PM ET
- Accepted
- Jul 23, 4:41 PM ET
- Size
- 15.4 KB